Anti-cancer DNA Vaccine Encoding p62 Protein

Creative Biolabs has extensive experience in vaccine development and advanced technology and top talents. In the development of anticancer drugs, we have also conducted a lot of in-depth and extensive research. We have now been able to skillfully develop various cancer therapies like DC vaccines, peptide/protein vaccines, DNA vaccines, and cancer vaccines vectored by viruses/bacteria targeting various cancer-specific antigens.

p62 Protein and p62-encoded DNA Vaccine

The treatment of cancer is still a hot issue, and cancer immunotherapy is a rising star in the field. The bottleneck in implementing this strategy is to find a highly ideal tumor antigen that can induce an immune response specific to cancer. A suitable tumor antigen should have good immunogenicity, should be essential for tumor cells but not for normal tissues and should be overexpressed in tumor cells without expression or rarely expressed in normal cells. P62, also known as sequestosome-1, is encoded by the gene SQSTM1 and is a major player in selective autophagy. P62 interacts with GATA4 to inhibit GATA-4-associated senescence and senescence-associated secretory phenotype by degrading GATA4. P62 is required for tumorigenesis and progression, but is dispensable for normal tissues, as demonstrated in p62 knockout mice. High levels of expression in tumor tissues are also a requirement for becoming a good cancer vaccine antigen. In this regard, it has been found in at least 10 different types of tumors that p62 is overexpressed in tumors compared to that in normal tissues.

After immunizing a patient with a DNA vaccine, the antigen can be expressed in the patient, thereby stimulating the body's immune system to produce immune responses against the antigen. The DNA vector used to express the target antigen is typically a circular, double-stranded bacterial DNA. The distinct difference between a DNA vaccine and a protein vaccine is that it can express an antigen intracellularly in the vaccinated patient, and thus the expressed protein can be subjected to protein modification and antigen presentation by an intracellular mechanism. This is why DNA vaccines can induce strong T cell and B cell responses. In addition, the DNA vaccine can simultaneously encode both forms of antigens that are protease-resistant and susceptible to protease degradation, and the combination of the two forms of antigens is more potent than the immune response caused by any one of the forms of the antigen alone.

Based on the above findings, we developed and evaluated a DNA vaccine capable of encoding p62. In mice and rat models with lung cancer, breast cancer, and melanoma, we have also observed its significant anti-cancer effects and antimetastatic activity.

Creative Biolabs is able to provide customers with advanced vaccine development technologies and services. In the development of cancer vaccines, we have conducted in-depth and extensive research on various targets found in the current studies. Therefore, we have experience in the design, development, and evaluation of tumor vaccines including DC vaccines, DNA vaccines, and peptides with various targets as antigens. We believe that we will be your most reliable partner!

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.